The landscape of obesity treatment is rapidly evolving with the emergence of several promising injectable therapies. Semaglutide's cousin , Cagrilintide , a GLP-1/GIP/GCG triple agonist , and a GLP-1 receptor https://nexaphresearchpeptides.com/